Back to results
US 8,945,582 B2Granted
Vaccine
AssigneeGlaxosmithkline Biologicals SA
InventorsHerve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
Life of this patent
Estimating the term…
Abstract
The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain adequate or improved level of protection against polio.
Claims14
An inactivated poliovirus (IPV) vaccine comprising:
- (a) diphtheria toxoid;
- (b) tetanus toxoid;
- (c) killed whole-cell Bordetella pertussis, substantially thiomersal free;
- or two or more acellular pertussis components (Pa) and;
- (d) inactivated poliovirus type 1, type 2 and type 3, wherein the inactivated poliovirus type 1 is present at a dose greater than 10 D-antigen units and less than 20 D-antigen units.
2 more elements
Dependencies are inferred from the claim text.